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Highly antiretroviral therapies (HAART) have been implemented to slow the 
progression of the human immunodeficiency virus (HIV).  Although these new advances 
in the medications for HIV-positive patients have contributed in longer life expectancy, 
comorbidities, such as cardiovascular disease, still cause higher number of deaths among 
HIV-positive patients than in the regular population.  Because of the intrinsic 
inflammation caused by the HIV virus, atherogenesis is more likely to occur and is driven 
by infected macrophages.  These macrophages are known to secrete cathepsins, but 
infection causes the macrophages not to perform their function properly as an immune 
agent.  I hypothesize that antiretroviral drugs play an important role in arterial remodeling 
by affecting cells within the artery and causing an alteration of cathepsin activity, leading 
to an increased risk of atherosclerosis in HIV patients.  To test this hypothesis, we 
incubated THP-1 monocytes with antiretroviral drugs efavirenz and tenofovir 
individually to observe any changes in cathepsin activity. These lysates were analyzed 
through multiplex cathepsin zymography and quantified through densitometry.  We 
found that our hypothesis held true for efavirenz and tenofovir in THP-1 monocytes, 
which caused decreased cathepsin K activity compared to vehicle controls.  Still, 
stimulation of peripheral blood mononuclear cells (PBMCs) with efavirenz and tenofovir 
caused differential effects.  Together, our data suggest that the HAART interaction with 
monocytes that are physiologically relevant to our system possibly contributes to the 








Currently, over 34 million people are infected with the human immunodeficiency 
virus (HIV) worldwide
1
.  Major advances in treatment with highly active antiretroviral 
therapy (HAART) have contributed to longer life expectancies, suppressed viral load, and 
slowed progression of Acquired Immunodeficiency Syndrome (AIDS) in HIV+ patients.    
Although combination HAART regimens are attributed to these improvements, prevalent 
cohort studies have shown that long-term exposure to these treatments increase 
progression of cardiovascular disease (CVD) in infected patients
2
.  HAART has been 
associated with adverse metabolic side effects such as hypertension, diabetes, and 
lipodystrophy that could be contributing to the cardiovascular complications
2-4
.   
Since cardiovascular risk was first suggested to be associated with antiretroviral 
exposure, few studies have examined the molecular mechanisms of HAART in the 
increased risk of cardiovascular disease in HIV+ patients.  Degradation of the 
extracellular matrix (ECM) within arteries, which serves as a key factor in atherogenesis 
and arterial stiffening, is prevalent in cardiovascular disorders.  This remodeling has been 
associated with cysteine proteases called cathepsins, specifically K, L, S, V, potent 
collagenases and elastases in the body that have been shown to be upregulated in 
atherosclerotic plaques in CVD 
5,6
.   
Expounding upon HAART and arterial remodeling through proteolytic activity, 
protease inhibitor azidothymidine (AZT) has been shown to promote arterial remodeling 
by increasing the proteolytic activity of cathepsins in mouse arteries
7
.   It has also been 
shown in preliminary studies in our lab that HIV+ patients in Ethiopia and South Africa 
on HIV regimens including reverse transcriptase inhibitors (RTIs) efavirenz and tenofovir 
 2 
have decreased cathepsin activity in their peripheral blood mononuclear cells (PBMCs).  
Studies in both clinical settings as well as animal models support that cathepsin activity 
should be further studied in association with cardiovascular disease in HIV+ patients.  
In light of previous studies, the purpose of this study is to investigate how 
HAART drugs alter cathepsin activity in monocytes, which could contribute to 
cardiovascular disease in HIV+ patients.   Therefore, the central hypothesis is that 
antiretroviral drugs efavirenz and tenofovir cause a decrease in cathepsin activity in 
monocytes.   Additionally, HAART conditioned monocytes are then hypothesized to 
contribute to cardiovascular disease by differentiating into macrophages as well as 
reducing cathepsin activity.  I propose to test these hypotheses first using a monocytic 
cell line and PBMCs, then to verify the results from in vitro conditions with in vivo 
samples from humans and mice.  This method will also aid in parsing out each specific 
antiretroviral effect on proteolytic activity within these cell types to provide insight on 




MATERIALS AND METHODS  
2. 1 Cell Culture and Treatment 
Human THP-1 acute monocytic leukemia cells (American Type Culture Collection) 
THP-1 monocytes were treated with vehicle controls (0.079% dimethyl sulfoxide 
[DMSO] (Sigma-Aldrich); 0.159% methanol (EMD)) or efavirenz (EFV) or tenofovir 
(TDF)  (100 uM each) (NIH AIDS Reagent Program)  in RPMI 1X 1640 medium 
(Corning Cell Gro) containing 10 % FBS, 0.05 % β-mercaptoethanol, 1 % L-glutamine, 
and 1 % penicillin/streptomycin for 24 h at 37 degrees Celsius prior to lysing. After 
consent from patients, human peripheral blood mononuclear cells were isolated from 
non-infected patients.  Whole blood samples were centrifuged for 30 minutes at 400 x g 
at 4°C after adding Ficoll-Paque (GE Healthcare) to separate layers of PBMCs from red 
blood cells.  Following centrifugation, the cells were collected, resuspended in PBS, and 
centrifuged for 10 minutes at 4°C.  The cells were then washed in RBC lysis buffer 
(0.83% ammonium chloride, 0.1% potassium bicarbonate, and 0.0037% EDTA) and 
centrifuged for 10 minutes at  4°C and subsequently with PBS to completely remove 
remaining red blood cells out of sample.  To remove platelets from PBMCs, the cells are 
then centrifuged at room temperature.  Cells were counted using the Vi-Cell XR 




Mouse Peripheral Blood Mononuclear Cell Lysates 
 Whole blood samples donated by Gleason Lab from Apolipoprotein E knockout 
(ApoE
-/-
) mice fed with 7.5 mg/kg EFV as a dosage.   EFV was diluted to 1 mg/ml and 
fed to the mouse based on the weight of the mouse.  Water was administered in an 
equivalent dose to the control group.  The blood samples were centrifuged for 30 minutes 
 4 
at 400 x g at 4°C after adding Ficoll-Paque (GE Healthcare) to separate layers of PBMCs 
from red blood cells.  Following centrifugation, the cells were collected, resuspended in 
PBS, and centrifuged for 10 minutes at 4°C.  The cells were then washed in RBC lysis 
buffer (0.83% ammonium chloride, 0.1% potassium bicarbonate, and 0.0037% EDTA) 
and centrifuged for 10 minutes at  4°C and subsequently with PBS to completely remove 
remaining red blood cells out of sample.  To remove platelets from PBMCs, the cells are 
then centrifuged at room temperature.   
 
2.3 Multiplex Cathepsin Zymography 
  Cathepsin zymography was performed on each of the samples 
8
. Prior to loading, 
non-reducing 5X loading buffer was added to all of the samples used for the experiment. 
Gel electrophoresis of the samples within 12.5% SDS-polyacrylamide gels containing 
gelatin at 4°C was performed for 2 hours at 100 V. Gels were removed and washed in 
cathepsin renaturing buffer (65 mM Tris buffer, pH 7.4 with 20 % glycerol) for 3 washes 
for 10 minutes each. Gels were then assayed in respective activity buffer (0.1 M sodium 
phosphate buffer, pH 6.0, 1 mM EDTA, and 2 mM DTT freshly added as well as 0.1 
acetate buffer, pH 4.0, 1 mM EDTA, and 2 mM DTT) for 30 minutes at room 
temperature. Then, fresh activity buffer was added to the respective gels and incubated 
for an overnight incubation at 37°C. After the overnight incubation, each gel was rinsed 
with distilled water and incubated for one hour in Coomassie Blue stain (10 % acetic 
acid, 25 % isopropanol, 4.5 % Coomassie Blue) followed by destain (10% isopropanol 
and 10% acetic acid).  Gels were then scanned using GE Healthcare LifeSciences 
ImageQuant LAS 4010. After imaging, each gel was quantified through densitometry 





2.4 Statistical Analyses  
Each experimental condition was repeated with a minimum of three biological 
replicates and each data point is presented as the mean value and standard deviation of 
the mean. Representative images are shown. Unpaired Student’s t tests were used to 



























3.1 Efavirenz and tenofovir significantly decreased cathepsin activity in monocytes 
To determine how tenofovir and efavirenz regulate cathepsin activity in monocytes 
during inflammatory conditions such as plaque formation, THP-1 monocytes were 
incubated with 100 μM efavirenz and tenofovir for 24 h.  The respective concentration 
was found in previous literature to observe a response at the highest possible non-
cytotoxic concentration that compared both antiretroviral drugs uniformly 
9,10
.  Both of 
these antiretroviral drugs decreased  mature cathepsin activity, efavirenz by fourfold  
(Fig. 1A) and tenofovir by twofold (Fig. 1B)  (n =3, p< 0.05) compared to each  
respective vehicle.  To ensure that efavirenz and tenofovir were the most active in 
decreasing cathepsin activity, monocytes were also incubated in 100 μM lamivudine 

















Figure 1. EFV & TDF decreases cathepsin activity in THP-1 monocytes. Densitometry 
showed that both of these antiretroviral drugs decreased  mature cathepsin activity, (A) efavirenz 





















































































Results also showed that (C) lamivudine does not significantly alter cathepsin activity (n = 3) 
compared to its respective vehicle.    
3.2 Efavirenz induced differential cathepsin activity in human PBMCs  
 Since efavirenz showed the most significant decrease in cathepsin activity in 
monocytes, the next objective was to see what kind of effects were  seen in human 
PBMCs, which include monocytes, macrophages, and other types of leukocytes intrinsic 
to inflammatory response. Cells were isolated from two different non-infected patients 
and subsequently incubated with 100 μM efavirenz for 24 h.  In patient 1, efavirenz 
increased cathepsin L activity while cells from patient 2 showed a decrease in cathepsin 











Figure 2. EFV causes differential effects on cathepsin L activity in human PBMCs.  
Efavirenz  stimulated variable cathepsin L acitivty in two different patients.   (patient 1: blue, 
patient 2: red) (n =3, error bars represent the mean   standard deviation). 
 
3.3 Efavirenz showed decreasing trends in cathepsin V activity in ApoE
-/-
mice 
 PBMCs from  ApoE
-/-
 mice that were fed 7.5 mg/kg efavirenz and compared to 
PBMCs from the control group that were fed water as the vehicle.  Results showed 
decreases in cathepsin V activity in the presence of efavirenz compared to the vehicle.  
Although not significant, the general trend among the mice was comparable to the 

































Figure 3. Efavirenz caused 




PBMCs.  Compared to the 
vehicle, efavirenz induced a 
decrease PBMCs from 
ApoE
-/- 
mice. (n = 3, error 




3.4 Combination HAART stimulated cathepsin activity in  monocytes 
 Since it is physiologically relevant, combination HAART was implemented in 
this study to observe changes in cathepsin activity in monocytes.  Using common drugs 
in regimens, monocytes were incubated in 5 μM efavirenz, tenofovir, and emtricitabine as 
well as efavirenz, tenofovir, and lamivudine in combination.  Lamivudine and 
emtricitabine are common NRTIs considered to be clinically interchangeable in 
combination with tenofovir and lamivudine; however, emtricitabine has been suggested 
to be pharmacologically different from lamivudine through interactions with tenofovir , 
thereby increasing its half-life.  Overall, the two drugs are comparable, so observing each 
particular drug in combination therapy was relevant
11
.  Cathepsin activity was 
significantly decreased in the presence of efavirenz, tenofovir, and lamivudine (Fig 4A.).  
Although not significant, cathepsin activity showed an increased in cathepsin activity in 




























































Figure 4: Combination HAART suggests that NRTI backbone stimulated differential 
cathepsin activity. (a) Cathepsin S activity decreased in the presence of combination HAART 
using efavirenz, tenofovir, and lamivudine(n =3, p< 0.05).  (b)  Increased cathepsin activity was 
































































Increased cathepsin activity has been assoiciated with arterial remodeling in 
atherosclerosis, abdominal aortic aneursyms, and arterial stiffening 
6
.  Plaque biology in 
atherosclerosis has been elucidated 
12
but how HIV antiretroviral drugs interact with the 
physiology in the arterial wall remains unknown.  There was a need to study treating a 
monocytic cell line and peripheral blood mononuclear cells (PBMCs) of patients in the 
presence of some common antiretroviral drug regimens to observe the effects that it has 
on cells that are prevalent in the inflammatory response in HIV as well as CVD. I 
proposed that stimulation of active cathepsins by efavirenz and tenofovir could provide 
insight in arterial remodeling in HIV+ patients, which could possibly contribute to the  
narrowing of the lumen and  impeding bloodflow involved in myocardial infarctions.  In 
THP-1 monocytes, there was significant reduction of cathepsin expression in the presence 
of the two drugs.  These results are similar compared to previous studies within our lab in 
clinical settings involving Ethiopian and South African HIV+ patients on regimens with 
efavirenz and tenofovir.  
 In human PBMCs from two different subjects, there was differential stimulation of 
cathepsin L activity.  The difference suggests  which suggested variability and possible 
patient-specific proteolytic activity as a factor in the treatment of HIV
13
.  Overall, these 
results suggest that these antiretroviral drugs affect cathepsin activity and this alteration 
could affect other cells within the vascular network.  Furthermore, PBMCs from ApoE
 -/ 
mice showed that trend of decreased mouse cathepsin L (homologue of human cathepsin 
V) activity compared to the vehicle.  In the future, I expect that a larger sample size will 
increase the significance of the decrease in mouse cathepsin L activity in the PBMCs. 
These results were useful to show if efavirenz promotes more proteolytic activity than 
 11 
what is seen at baseline in induced atherosclerosis in mice.  Also, the decreases in 
cathepsin acitivity matched what we have seen in monocytes.  
Limitations in this study included the cell types used within this study.  By using 
monocytes, interactions with other cell types within the body was not taken into account 
in this study.  Also, by incubating PBMCs from non-infected patients  with efavirenz 
after they were isolated from the blood, this study did not take into account processing of 
the drug  into metabolites, thereby causing a physiological response through  metabolite-
cell interactions.  are more Lastly, proteolytic activity was only analyzed and was not 
compaired to physical arterial remodeling.  However, future studies will include looking 
at arterial stiffening and other remodeling characteristics seen in the mice to make this 
study impactful. 
Also, inherent inflammation involves endothelial cell-monocyte interaction as well as 
inflammatory cytokines that activate cell adhesion molecules to promote monocyte 
transendothelial migration
14
.  To further study how this contributes to proteolysis and 
vascular remodeling in atherosclerosis,   future studies will include a co-culture using 
human PBMCs and human arterial endothelial cells (HAECs) incubated with 
antiretroviral drugs can be to model an arterial system of a HIV+ patient under HAART 
regimen.   
In a physiological relevant regimen of a HIV+ patient, combination HAART therapy 
stimulated cathepsin activity in monocytes.  Using lamivudine or emtricitabine as the 
nucleoside reverse transcriptase inhibtor (NRTI) backbone of the antiretroviral regimen 
stimulated differential effects in cathepsin expression, which enhances the need for 
HAART drugs to be examined closely in terms of molecular mechanisms.    
In mechanistic terms, Keegan et al. showed that  increases in cathepsin K and V 
activity, which are the most potent collagenase and elastase, respectively, and key 
phosphorylation of the Jun N-terminal kinase linked intracellular pathways of TNFα and 
monocyte binding stimulation to cathepsin activity
14
.   In coordination with this study, 
 12 
oxidative stress and an increase in reactive oxygen species causes vascular damage 
during inflammation, so future studies could include  the observation of  increasing 
oxidative stress, thereby increasing recrutiment of PBMCs and/or THP-1 monocytes by 
endothelial cells
15
.  Cathepsin activity should then be analyzed by multiplex cathepsin 
zymography to help explain specific protease activity that could ultimately lead to 
establishing mechanisms between atherosclerosis and HIV infection
8
.   
Overall, this study is a novel way to approach the molecular mechanisms of HAART 
drugs have on monocytes.  HAART interactions with each other in combination therapy 
affect protease activity, so this proposed study provides insight on focusing on potential 
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